<DOC>
	<DOCNO>NCT00867334</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability imatinib mesylate combination panitumumab treatment stage IV colorectal cancer spread liver . It also assess whether imatinib mesylate , either alone combination panitumumab , effective treat type cancer . In addition , study evaluate feasibility predefined lab score whether predict patient respond treatment imatinib mesylate .</brief_summary>
	<brief_title>New Individualized Therapy Trial Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients ≥ 18 year age . Histologically documented diagnosis Stage IV Metastatic Colorectal Cancer Liver Metastases , refractory progressive least one ( 1 ) prior line therapy must include fluoropyrimidine ( 5fluorouracil capecitabine ) AND ( oxaliplatin OR irinotecan ) , i.e . FOLFOX , FOLFIRI , XELOX , XELIRI . Documentation wild type kRas expression liver lesion . At least one measurable site disease ( define Response Evaluation Criteria Solid Tumors , see Appendix 3 ) , response assessment criterion , appropriate . Must ≥ 1 measurable liver lesion access CT guide biopsy . Performance status 0,1 , 2 ( ECOG ) . Adequate end organ function , define follow : total bilirubin &lt; 1.5 x ULN , SGOT SGPT &lt; 2.5 x UNL , creatinine &lt; 1.5 x ULN , ANC &gt; 1.5 x 10^9/L , platelet &gt; 100 x 10^9/L . Life expectancy least 3 month . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Female patient reproductive potential must agree employ effective barrier method birth control throughout study 7 day follow discontinuation study drug . Written , voluntary inform consent . Patient receive investigational agent within 28 day first day study drug dosing , unless disease rapidly progress . Patient &lt; 5 year free another primary malignancy except : primary malignancy neither currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Patient Grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) Female patient pregnant breastfeeding . Patient severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal disease , active uncontrolled infection ) . Patient known brain metastasis treat definitive therapy stable disease ≥ 4 week . Patient know chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . Patient known diagnosis human immunodeficiency virus ( HIV ) infection . Patient receive chemotherapy within 2 week ( 6 week nitrosourea mitomycinC ) prior study entry , unless disease rapidly progress . Patient previously receive radiotherapy ≥ 25 % bone marrow Patient major surgery within 2 week prior study entry . Patient significant history noncompliance medical regimen inability grant reliable informed consent . Patients intolerant imatinib mesylate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>colorectal neoplasm</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>imatinib mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>c-kit receptor</keyword>
	<keyword>Receptor</keyword>
	<keyword>Platelet-Derived Growth Factor alpha</keyword>
</DOC>